Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Lancet Infect Dis
    February 2021
  1. INZAULE SC, Tessema SK, Kebede Y, Ogwell Ouma AE, et al
    Genomic-informed pathogen surveillance in Africa: opportunities and challenges.
    Lancet Infect Dis. 2021 Feb 12. pii: S1473-3099(20)30939.
    >> Share

  2. DOOLEY KE, Rosenkranz SL, Conradie F, Moran L, et al
    QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Lancet Infect Dis. 2021 Feb 12. pii: S1473-3099(20)30770.
    >> Share

    January 2021
  3. SCRIBA TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, et al
    Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
    Lancet Infect Dis. 2021 Jan 25. pii: S1473-3099(20)30914.
    >> Share

    December 2020
  4. HENGEL B, Causer L, Matthews S, Smith K, et al
    A decentralised point-of-care testing model to address inequities in the COVID-19 response.
    Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30859.
    >> Share

  5. SAMER C, Lacombe K, Calmy A
    Cyber harassment of female scientists will not be the new norm.
    Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30944.
    >> Share

  6. POUSTCHI H, Darvishian M, Mohammadi Z, Shayanrad A, et al
    SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Lancet Infect Dis. 2020 Dec 15. pii: S1473-3099(20)30858.
    >> Share

  7. NKEREUWEM E, Togun T, Gomez MP, Szekely R, et al
    Comparing accuracy of lipoarabinomannan urine tests for diagnosis of pulmonary tuberculosis in children from four African countries: a cross-sectional study.
    Lancet Infect Dis. 2020 Dec 11. pii: S1473-3099(20)30598.
    >> Share

  8. HAMADA Y, Gupta RK, Matteelli A, Abubakar I, et al
    Predictive performance of interferon-gamma release assays and tuberculin skin tests.
    Lancet Infect Dis. 2020;20:1371-1372.
    >> Share

    November 2020
  9. KAZI F, Mushtaq A
    Primary care of patients with HIV.
    Lancet Infect Dis. 2020 Nov 27. pii: S1473-3099(20)30925.
    >> Share

  10. SHROUFI A, Chiller T, Jordan A, Denning DW, et al
    Ending deaths from HIV-related cryptococcal meningitis by 2030.
    Lancet Infect Dis. 2020 Nov 27. pii: S1473-3099(20)30909.
    >> Share

  11. KENYON C, Manoharan-Basil SS
    Macrolide consumption and resistance in Mycoplasma genitalium.
    Lancet Infect Dis. 2020;20:1235-1236.
    >> Share

    October 2020
  12. ETARD JF
    Immunity to Ebola virus: the full picture is being revealed.
    Lancet Infect Dis. 2020 Oct 13. pii: S1473-3099(20)30793.
    >> Share

  13. KIRBY T
    Evelina Tacconelli-two viruses, two wars.
    Lancet Infect Dis. 2020;20:1132.
    >> Share

    September 2020
  14. HIRONS A, Khoury G, Purcell DFJ
    Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent.
    Lancet Infect Dis. 2020 Sep 25. pii: S1473-3099(20)30328.
    >> Share

    August 2020
  15. MADHI SA, Mutsaerts EA, Izu A, Boyce W, et al
    Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
    Lancet Infect Dis. 2020 Aug 25. pii: S1473-3099(20)30289.
    >> Share

    July 2020
  16. KIRBY T
    Cabotegravir, a new option for PrEP.
    Lancet Infect Dis. 2020;20:781.
    >> Share

    June 2020
  17. RODRIGUEZ TUDELA JL, Cole DC, Ravasi G, Bruisma N, et al
    Integration of fungal diseases into health systems in Latin America.
    Lancet Infect Dis. 2020 Jun 30. pii: S1473-3099(20)30469.
    >> Share

  18. SENA AC, Bachmann L, Johnston C, Wi T, et al
    Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.
    Lancet Infect Dis. 2020 Jun 19. pii: S1473-3099(20)30171.
    >> Share

    May 2020
  19. DIVALA TH, Fielding KL, Kandulu C, Nliwasa M, et al
    Utility of broad-spectrum antibiotics for diagnosing pulmonary tuberculosis in adults: a systematic review and meta-analysis.
    Lancet Infect Dis. 2020 May 18. pii: S1473-3099(20)30143.
    >> Share

    April 2020
  20. YANG F, Zhang TP, Tang W, Ong JJ, et al
    Pay-it-forward gonorrhoea and chlamydia testing among men who have sex with men in China: a randomised controlled trial.
    Lancet Infect Dis. 2020 Apr 28. pii: S1473-3099(20)30172.
    >> Share

  21. FOLEGATTI PM, Bittaye M, Flaxman A, Lopez FR, et al
    Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
    Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30160.
    >> Share

  22. GROOME MJ, Fairlie L, Morrison J, Fix A, et al
    Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30001.
    >> Share

  23. MUSHTAQ A
    New guidelines for latent tuberculosis.
    Lancet Infect Dis. 2020;20:414.
    >> Share

  24. CHOUCHANA L, Pariente A, Pannier E, Tsatsaris V, et al
    Dolutegravir and neural tube defects: a new insight.
    Lancet Infect Dis. 2020;20:405-406.
    >> Share

    March 2020
  25. KALLAS EG, Precioso AR, Palacios R, Thome B, et al
    Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.
    Lancet Infect Dis. 2020 Mar 24. pii: S1473-3099(20)30023.
    >> Share

  26. MARAIS BJ, Chakaya J, Swaminathan S, Fox GJ, et al
    Tackling long-term morbidity and mortality after successful tuberculosis treatment.
    Lancet Infect Dis. 2020 Mar 23. pii: S1473-3099(20)30167.
    >> Share

  27. TAPIA MD, Sow SO, Ndiaye BP, Mbaye KD, et al
    Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
    Lancet Infect Dis. 2020 Mar 19. pii: S1473-3099(20)30016.
    >> Share

  28. BARR DA, Lewis JM, Feasey N, Schutz C, et al
    Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data.
    Lancet Infect Dis. 2020 Mar 13. pii: S1473-3099(19)30695.
    >> Share

  29. KELLER PM, Furrer H
    Think tuberculosis-but is thinking enough?
    Lancet Infect Dis. 2020 Mar 13. pii: S1473-3099(20)30138.
    >> Share

  30. MBOPI-KEOU FX, Kalla GCM, Anankeu P, Pondi JE, et al
    Launching HIV self-testing in a multicultural setting in Cameroon.
    Lancet Infect Dis. 2020;20:286-287.
    >> Share

    February 2020
  31. WILLIAMS CM, Abdulwhhab M, Birring SS, De Kock E, et al
    Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies.
    Lancet Infect Dis. 2020 Feb 18. pii: S1473-3099(19)30707.
    >> Share

  32. LAXMINARAYAN R, Van Boeckel T, Frost I, Kariuki S, et al
    The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later.
    Lancet Infect Dis. 2020 Feb 11. pii: S1473-3099(20)30003.
    >> Share

    January 2020
  33. TOWN K, Field N, Harris SR, Sanchez-Buso L, et al
    Phylogenomic analysis of Neisseria gonorrhoeae transmission to assess sexual mixing and HIV transmission risk in England: a cross-sectional, observational, whole-genome sequencing study.
    Lancet Infect Dis. 2020 Jan 21. pii: S1473-3099(19)30610.
    >> Share

  34. JOLLY AM, Dillon JR
    Phylogenomic analysis of Neisseria gonorrhoeae: a promising tool for tracking putative gonococcal sexual networks.
    Lancet Infect Dis. 2020 Jan 21. pii: S1473-3099(19)30751.
    >> Share

  35. CLARKE DK, Xu R, Matassov D, Latham TE, et al
    Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
    Lancet Infect Dis. 2020 Jan 14. pii: S1473-3099(19)30614.
    >> Share

  36. DONOVAN J, Thu DDA, Phu NH, Dung VTM, et al
    Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study.
    Lancet Infect Dis. 2020 Jan 7. pii: S1473-3099(19)30649.
    >> Share

  37. CRESSWELL FV, Tugume L, Bahr NC, Kwizera R, et al
    Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study.
    Lancet Infect Dis. 2020 Jan 7. pii: S1473-3099(19)30550.
    >> Share

  38. BROGER T, Muyoyeta M, Kerkhoff AD, Denkinger CM, et al
    Tuberculosis test results using fresh versus biobanked urine samples with FujiLAM.
    Lancet Infect Dis. 2020;20:22-23.
    >> Share

    December 2019
  39. COTTON MF, Rabie H
    HIV outbreak in children in Pakistan: localised or more widespread?
    Lancet Infect Dis. 2019 Dec 19. pii: S1473-3099(19)30746.
    >> Share

  40. MIR F, Mahmood F, Siddiqui AR, Baqi S, et al
    HIV infection predominantly affecting children in Sindh, Pakistan, 2019: a cross-sectional study of an outbreak.
    Lancet Infect Dis. 2019 Dec 19. pii: S1473-3099(19)30743.
    >> Share

  41. AUGUSTO GF
    HIV self-testing kits enjoy successful launch in Portugal.
    Lancet Infect Dis. 2019;19:1289.
    >> Share

  42. SHARLAND M, Gandra S, Huttner B, Moja L, et al
    Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool.
    Lancet Infect Dis. 2019;19:1278-1280.
    >> Share

    November 2019
  43. LOOKER KJ, Welton NJ, Sabin KM, Dalal S, et al
    Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data.
    Lancet Infect Dis. 2019 Nov 18. pii: S1473-3099(19)30470.
    >> Share

  44. DARA M, Ehsani S, Mozalevskis A, Vovc E, et al
    Tuberculosis, HIV, and viral hepatitis diagnostics in eastern Europe and central Asia: high time for integrated and people-centred services.
    Lancet Infect Dis. 2019 Nov 15. pii: S1473-3099(19)30524.
    >> Share

    October 2019

  45. Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017.
    Lancet Infect Dis. 2019 Oct 30. pii: S1473-3099(19)30410.
    >> Share

  46. HILL SC, Vasconcelos J, Neto Z, Jandondo D, et al
    Emergence of the Asian lineage of Zika virus in Angola: an outbreak investigation.
    Lancet Infect Dis. 2019;19:1138-1147.
    >> Share

  47. BLOWER S, Okano JT
    Precision public health and HIV in Africa.
    Lancet Infect Dis. 2019;19:1050-1052.
    >> Share

    September 2019

  48. The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet Infect Dis. 2019 Sep 24. pii: S1473-3099(19)30418.
    >> Share

  49. AKIYAMA MJ, Cleland CM, Lizcano JA, Cherutich P, et al
    Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Lancet Infect Dis. 2019 Sep 17. pii: S1473-3099(19)30264.
    >> Share

  50. RAHIMI S
    Dolutegravir becomes first choice for HIV.
    Lancet Infect Dis. 2019;19:937-938.
    >> Share

    August 2019
  51. AGINS BD, Ikeda DJ, Reid MJA, Goosby E, et al
    Improving the cascade of global tuberculosis care: moving from the "what" to the "how" of quality improvement.
    Lancet Infect Dis. 2019 Aug 22. pii: S1473-3099(19)30420.
    >> Share

  52. RHEIN J, Huppler Hullsiek K, Tugume L, Nuwagira E, et al
    Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.
    Lancet Infect Dis. 2019;19:843-851.
    >> Share

  53. TENFORDE MW, Jarvis JN
    HIV-associated cryptococcal meningitis: ongoing challenges and new opportunities.
    Lancet Infect Dis. 2019;19:793-794.
    >> Share

    July 2019
  54. MUHINDO MK, Jagannathan P, Kakuru A, Opira B, et al
    Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial.
    Lancet Infect Dis. 2019 Jul 12. pii: S1473-3099(19)30299.
    >> Share

  55. TENFORDE MW, Mokomane M, Leeme TB, Tlhako N, et al
    Mortality in adult patients with culture-positive and culture-negative meningitis in the Botswana national meningitis survey: a prevalent cohort study.
    Lancet Infect Dis. 2019;19:740-749.
    >> Share

  56. ARIF F
    HIV crisis in Sindh, Pakistan: the tip of the iceberg.
    Lancet Infect Dis. 2019;19:695-696.
    >> Share

  57. THE LANCET INFECTIOUS DISEASES
    HIV epidemics in Pakistan.
    Lancet Infect Dis. 2019;19:671.
    >> Share

    June 2019
  58. LIN C, Slama J, Gonzalez P, Goodman MT, et al
    Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis.
    Lancet Infect Dis. 2019 Jun 13. pii: S1473-3099(19)30164.
    >> Share

  59. SUAREZ I, Maria Funger S, Jung N, Lehmann C, et al
    Severe disseminated tuberculosis in HIV-negative refugees.
    Lancet Infect Dis. 2019 Jun 7. pii: S1473-3099(19)30162.
    >> Share

    May 2019
  60. BROGER T, Sossen B, du Toit E, Kerkhoff AD, et al
    Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study.
    Lancet Infect Dis. 2019 May 30. pii: S1473-3099(19)30001.
    >> Share

  61. DRAIN PK, Heichman KA, Wilson D
    A new point-of-care test to diagnose tuberculosis.
    Lancet Infect Dis. 2019 May 30. pii: S1473-3099(19)30053.
    >> Share

  62. BURKI T
    Tuberculosis mortality targets off-track.
    Lancet Infect Dis. 2019;19:472.
    >> Share

    April 2019
  63. BURKI T
    The end of HIV in the USA.
    Lancet Infect Dis. 2019;19:365-366.
    >> Share

    March 2019
  64. VAN EIJK AM, Larsen DA, Kayentao K, Koshy G, et al
    Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis.
    Lancet Infect Dis. 2019 Mar 25. pii: S1473-3099(18)30732.
    >> Share

  65. INZAULE SC, Hamers RL, Doherty M, Shafer RW, et al
    Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.
    Lancet Infect Dis. 2019 Mar 19. pii: S1473-3099(18)30710.
    >> Share

  66. WAHID B
    An update on the severe outbreak of HIV in Kot Imrana, Pakistan.
    Lancet Infect Dis. 2019;19:241.
    >> Share

  67. GOFF DA, Kullar R, Laxminarayan R, Mendelson M, et al
    Twitter to engage, educate, and advocate for global antibiotic stewardship and antimicrobial resistance.
    Lancet Infect Dis. 2019;19:229-231.
    >> Share

  68. BENGTSON AM, Sanfilippo AM, Hughes BL, Savitz DA, et al
    Maternal immunisation and neonatal infection of hepatitis A or B virus - Authors' reply.
    Lancet Infect Dis. 2019;19:238-239.
    >> Share

  69. ZHOU YH
    Maternal immunisation and neonatal infection of hepatitis A or B virus.
    Lancet Infect Dis. 2019;19:238.
    >> Share

    February 2019
  70. ZURCHER K, Ballif M, Fenner L, Borrell S, et al
    Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study.
    Lancet Infect Dis. 2019 Feb 7. pii: S1473-3099(18)30673.
    >> Share

  71. ABOUD M, Kaplan R, Lombaard J, Zhang F, et al
    Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
    Lancet Infect Dis. 2019 Feb 4. pii: S1473-3099(19)30036.
    >> Share

  72. WALKER S, Stoove M, Wilson M, Higgs P, et al
    Understanding HIV and hepatitis C virus risk among incarcerated young men with histories of injecting drug use.
    Lancet Infect Dis. 2019;19:130-131.
    >> Share

    January 2019
  73. WHITWORTH HS, Badhan A, Boakye AA, Takwoingi Y, et al
    Clinical utility of existing and second-generation interferon-gamma release assays for diagnostic evaluation of tuberculosis: an observational cohort study.
    Lancet Infect Dis. 2019 Jan 14. pii: S1473-3099(18)30613.
    >> Share

  74. LI KT, Tang W, Wu D, Huang W, et al
    Pay-it-forward strategy to enhance uptake of dual gonorrhea and chlamydia testing among men who have sex with men in China: a pragmatic, quasi-experimental study.
    Lancet Infect Dis. 2019;19:76-82.
    >> Share

  75. THE LANCET INFECTIOUS DISEASES
    HIV in Europe: a long road still lies ahead.
    Lancet Infect Dis. 2019;19:1.
    >> Share

    December 2018
  76. CUDAHY PGT, Andrews JR, Bilinski A, Dowdy DW, et al
    Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings.
    Lancet Infect Dis. 2018 Dec 13. pii: S1473-3099(18)30443.
    >> Share

  77. KHAN PY, Yates TA, Osman M, Warren RM, et al
    Transmission of drug-resistant tuberculosis in HIV-endemic settings.
    Lancet Infect Dis. 2018 Dec 13. pii: S1473-3099(18)30537.
    >> Share

  78. PETERS JS, Andrews JR, Hatherill M, Hermans S, et al
    Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings.
    Lancet Infect Dis. 2018 Dec 13. pii: S1473-3099(18)30477.
    >> Share

  79. LINDSEY BB, Armitage EP, Kampmann B, de Silva TI, et al
    The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review.
    Lancet Infect Dis. 2018 Dec 12. pii: S1473-3099(18)30490.
    >> Share

  80. BENGTSON AM, Sanfilippo AM, Hughes BL, Savitz DA, et al
    Maternal immunisation to improve the health of HIV-exposed infants.
    Lancet Infect Dis. 2018 Dec 7. pii: S1473-3099(18)30545.
    >> Share

  81. BRINK AJ, Mendelson M
    Be AWaRe: new metrics for paediatric antibiotic stewardship.
    Lancet Infect Dis. 2018 Dec 3. pii: S1473-3099(18)30557.
    >> Share


  82. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study.
    Lancet Infect Dis. 2018;18:1329-1349.
    >> Share

  83. BURKI T
    HIV in China: a changing epidemic.
    Lancet Infect Dis. 2018;18:1311-1312.
    >> Share

    November 2018
  84. HEMELAAR J, Elangovan R, Yun J, Dickson-Tetteh L, et al
    Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis.
    Lancet Infect Dis. 2018 Nov 30. pii: S1473-3099(18)30647.
    >> Share

  85. PARASKEVIS D, Hatzakis A
    Global molecular epidemiology of HIV-1: the chameleon challenge.
    Lancet Infect Dis. 2018 Nov 30. pii: S1473-3099(18)30687.
    >> Share

  86. DELANY-MORETLWE S, Lombard C, Baron D, Bekker LG, et al
    Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2018;18:1241-1250.
    >> Share

  87. GENG EH, Glidden DV, Padian N
    Strengthening HIV-prevention trials: a dose of implementation science?
    Lancet Infect Dis. 2018;18:1166-1168.
    >> Share

    October 2018
  88. STONE J, Fraser H, Lim AG, Walker JG, et al
    Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.
    Lancet Infect Dis. 2018 Oct 29. pii: S1473-3099(18)30469.
    >> Share

  89. LOYSE A, Burry J, Cohn J, Ford N, et al
    Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.
    Lancet Infect Dis. 2018 Oct 18. pii: S1473-3099(18)30493.
    >> Share

  90. VARIAVA E, Martinson N
    Occult rifampicin-resistant tuberculosis: better assays are needed.
    Lancet Infect Dis. 2018 Oct 17. pii: S1473-3099(18)30550.
    >> Share

  91. KISSINGER P, Muzny CA, Mena LA, Lillis RA, et al
    Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial.
    Lancet Infect Dis. 2018 Oct 5. pii: S1473-3099(18)30423.
    >> Share

  92. HUGHES G, Fifer H
    Point-of-care tests for chlamydia and gonorrhoea in Indigenous communities.
    Lancet Infect Dis. 2018;18:1054-1055.
    >> Share

    September 2018
  93. DIVALA TH, Mungwira RG, Mawindo PM, Nyirenda OM, et al
    Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.
    Lancet Infect Dis. 2018 Sep 5. pii: S1473-3099(18)30415.
    >> Share

    August 2018
  94. ADENIS AA, Valdes A, Cropet C, McCotter OZ, et al
    Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study.
    Lancet Infect Dis. 2018 Aug 23. pii: S1473-3099(18)30354.
    >> Share

  95. BURKI T
    The USA's HIV problem.
    Lancet Infect Dis. 2018;18:840-841.
    >> Share

    July 2018
  96. SAGARA I, Healy SA, Assadou MH, Gabriel EE, et al
    Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.
    Lancet Infect Dis. 2018 Jul 27. pii: S1473-3099(18)30344.
    >> Share

  97. WOODHALL SC, Gorwitz RJ, Migchelsen SJ, Gottlieb SL, et al
    Advancing the public health applications of Chlamydia trachomatis serology.
    Lancet Infect Dis. 2018 Jul 5. pii: S1473-3099(18)30159.
    >> Share

  98. NKENGASONG JN, Mbopi-Keou FX, Peeling RW, Yao K, et al
    Laboratory medicine in Africa since 2008: then, now, and the future.
    Lancet Infect Dis. 2018 Jul 3. pii: S1473-3099(18)30120.
    >> Share

  99. KALLA GCM, Voundi EV, Angwafo F 3rd, Belec L, et al
    Mass screening for hepatitis B and C and HIV in sub-Saharan Africa.
    Lancet Infect Dis. 2018;18:716.
    >> Share

    June 2018
  100. ZAID M, Afzal MS
    HIV outbreak in Pakistan.
    Lancet Infect Dis. 2018;18:601.
    >> Share

    May 2018
  101. MENDELSON M, Hamer DH
    Out of the frying pan and into the fire.
    Lancet Infect Dis. 2018 May 17. pii: S1473-3099(18)30244.
    >> Share

  102. SEEDAT F, Hargreaves S, Nellums LB, Ouyang J, et al
    How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review.
    Lancet Infect Dis. 2018 May 16. pii: S1473-3099(18)30117.
    >> Share

    April 2018
  103. VARIAVA E, Martinson N
    Drug-resistant tuberculosis: the rise of the monos.
    Lancet Infect Dis. 2018 Apr 20. pii: S1473-3099(18)30247.
    >> Share

  104. MENDELSON M, Brink A, Gouws J, Mbelle N, et al
    The One Health stewardship of colistin as an antibiotic of last resort for human health in South Africa.
    Lancet Infect Dis. 2018 Apr 16. pii: S1473-3099(18)30119.
    >> Share

  105. LABORDE-BALEN G, Taverne B, Ndour CT, Kouanfack C, et al
    The fourth HIV epidemic.
    Lancet Infect Dis. 2018;18:379-380.
    >> Share

    March 2018
  106. WALZL G, McNerney R, du Plessis N, Bates M, et al
    Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.
    Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30111.
    >> Share

  107. FIFER H, Cole M, Hughes G, Padfield S, et al
    Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study.
    Lancet Infect Dis. 2018 Mar 6. pii: S1473-3099(18)30122.
    >> Share

  108. BOYLES T
    Xpert Ultra's place in the diagnosis of tuberculous meningitis.
    Lancet Infect Dis. 2018;18:248-249.
    >> Share

    February 2018
  109. FERLAZZO G, Mohr E, Laxmeshwar C, Hewison C, et al
    Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Lancet Infect Dis. 2018 Feb 13. pii: S1473-3099(18)30100.
    >> Share

  110. KOUDOU BG, de Souza DK, Biritwum NK, Bougma R, et al
    Elimination of lymphatic filariasis in west African urban areas: is implementation of mass drug administration necessary?
    Lancet Infect Dis. 2018 Feb 2. pii: S1473-3099(18)30069.
    >> Share

  111. COLEMAN BW, Sereti I, Bishop R, Smith BR, et al
    Upbeat nystagmus in an HIV-positive patient with a tuberculoma in the medulla.
    Lancet Infect Dis. 2018;18:225.
    >> Share

  112. ASSEFA Y
    Expansion of the WHO public health approach to HIV.
    Lancet Infect Dis. 2018;18:143-144.
    >> Share

    January 2018
  113. DESAI M, Hill J, Fernandes S, Walker P, et al
    Prevention of malaria in pregnancy.
    Lancet Infect Dis. 2018 Jan 30. pii: S1473-3099(18)30064.
    >> Share

  114. MCCLELLAND RS, Lingappa JR, Srinivasan S, Kinuthia J, et al
    Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study.
    Lancet Infect Dis. 2018 Jan 25. pii: S1473-3099(18)30058.
    >> Share

  115. PASSMORE JS, Jaspan HB
    Vaginal microbes, inflammation, and HIV risk in African women.
    Lancet Infect Dis. 2018 Jan 25. pii: S1473-3099(18)30061.
    >> Share

  116. VAN LAARHOVEN A, Dian S, Aguirre-Gamboa R, Avila-Pacheco J, et al
    Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study.
    Lancet Infect Dis. 2018 Jan 23. pii: S1473-3099(18)30053.
    >> Share

  117. DARA M, Zachariah R
    Ending tuberculosis calls for leaving no one behind.
    Lancet Infect Dis. 2018 Jan 8. pii: S1473-3099(17)30746.
    >> Share

  118. ZOU H, Tucker JD, Fan S, Xu J, et al
    Learning about HIV the hard way: HIV among Chinese MSM attending university.
    Lancet Infect Dis. 2018;18:16-18.
    >> Share

    December 2017
  119. MOLINA JM, Charreau I, Chidiac C, Pialoux G, et al
    Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.
    Lancet Infect Dis. 2017 Dec 8. pii: S1473-3099(17)30725.
    >> Share


  120. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015.
    Lancet Infect Dis. 2017 Dec 6. pii: S1473-3099(17)30703.
    >> Share

    November 2017
  121. YERLY S, Calmy A
    Time to overcome pretreatment HIV drug resistance.
    Lancet Infect Dis. 2017 Nov 30. pii: S1473-3099(17)30709.
    >> Share

  122. DORMAN SE, Schumacher SG, Alland D, Nabeta P, et al
    Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study.
    Lancet Infect Dis. 2017 Nov 30. pii: S1473-3099(17)30691.
    >> Share

  123. GUPTA RK, Gregson J, Parkin N, Haile-Selassie H, et al
    HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.
    Lancet Infect Dis. 2017 Nov 30. pii: S1473-3099(17)30702.
    >> Share

  124. LIN C, Franceschi S, Clifford GM
    Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis.
    Lancet Infect Dis. 2017 Nov 17. pii: S1473-3099(17)30653.
    >> Share

  125. HERMANS LE, Moorhouse M, Carmona S, Grobbee DE, et al
    Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Lancet Infect Dis. 2017 Nov 17. pii: S1473-3099(17)30681.
    >> Share

  126. CASTAGNA A, Galli L
    Stepping up HIV-1 low-level viraemia surveillance in South Africa.
    Lancet Infect Dis. 2017 Nov 17. pii: S1473-3099(17)30680.
    >> Share

  127. ZELENEV A, Li J, Mazhnaya A, Basu S, et al
    Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.
    Lancet Infect Dis. 2017 Nov 15. pii: S1473-3099(17)30676.
    >> Share

  128. HILL AM, Venter F
    The unexpected success of NRTIs in second-line treatment.
    Lancet Infect Dis. 2017 Nov 3. pii: S1473-3099(17)30631.
    >> Share

  129. HAKIM JG, Thompson J, Kityo C, Hoppe A, et al
    Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
    Lancet Infect Dis. 2017 Nov 3. pii: S1473-3099(17)30630.
    >> Share

  130. COUSINS S
    HIV and antenatal care in Sri Lanka: a global health success.
    Lancet Infect Dis. 2017;17:1126.
    >> Share

    October 2017
  131. ABEL L, Fellay J, Haas DW, Schurr E, et al
    Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.
    Lancet Infect Dis. 2017 Oct 27. pii: S1473-3099(17)30623.
    >> Share

  132. FORD N, Ball A, Baggaley R, Vitoria M, et al
    The WHO public health approach to HIV treatment and care: looking back and looking ahead.
    Lancet Infect Dis. 2017 Oct 20. pii: S1473-3099(17)30482.
    >> Share

  133. CAMBIANO V, Miners A, Dunn D, McCormack S, et al
    Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Lancet Infect Dis. 2017 Oct 17. pii: S1473-3099(17)30540.
    >> Share

  134. REVILL P, Dwyer E
    Pre-exposure prophylaxis is cost-effective for HIV in the UK.
    Lancet Infect Dis. 2017 Oct 17. pii: S1473-3099(17)30594.
    >> Share

    September 2017
  135. BEIGEL JH, Bao Y, Beeler J, Manosuthi W, et al
    Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
    Lancet Infect Dis. 2017 Sep 22. pii: S1473-3099(17)30476.
    >> Share

  136. BAHR NC, Nuwagira E, Evans EE, Cresswell FV, et al
    Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study.
    Lancet Infect Dis. 2017 Sep 14. pii: S1473-3099(17)30474.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016